成纤维细胞活化蛋白抑制剂PET显像评估胰腺肿瘤的性能:系统评价与Meta分析
该系统评价与Meta分析检索截至2023年9月18日的PubMed和Web of Science数据库,比较FAPI PET与[18F]FDG PET在胰腺癌原发灶、淋巴结转移和远处转移评估中的诊断效能。FAPI PET在检测原发灶、淋巴结转移和远处转移方面的敏感度均高于FDG PET,原发灶SUVmax也显著更高。作者认为FAPI PET可能成为评估胰腺癌的更好替代方法。
要点
- FAPI PET检测胰腺癌原发灶的敏感度为1.000(95%CI 0.999-1.000),高于FDG PET的0.889(95%CI 0.788-0.966)。
- FAPI PET检测淋巴结转移的敏感度为0.624(95%CI 0.391-0.834),高于FDG PET的0.373(95%CI 0.163-0.606)。
- FAPI PET检测远处转移的敏感度为0.965(95%CI 0.804-1.000),高于FDG PET的0.889(95%CI 0.689-0.999)。
核心结论
- 与[18F]FDG PET/CT相比,FAPI PET显像显示出更高的敏感度和SUVmax,作者认为该方法可有效用于胰腺癌的评估。
研究设计与样本
- 系统评价与Meta分析,检索PubMed和Web of Science数据库截至2023年9月18日发表的文献,纳入使用放射性核素标记的FAPI和FDG作为PET诊断示踪剂评估胰腺癌患者适用性的研究。
关键影像表现/征象
- FAPI PET显像中原发灶的SUVmax显著高于FDG显像,平均差(MD)=7.51(95%CI 5.34-9.67)。
诊断标准与关键数值
- FAPI PET检测原发灶的敏感度为1.000(95%CI 0.999-1.000),FDG PET为0.889(95%CI 0.788-0.966)。
- FAPI PET检测淋巴结转移的敏感度为0.624(95%CI 0.391-0.834),FDG PET为0.373(95%CI 0.163-0.606)。
- FAPI PET检测远处转移的敏感度为0.965(95%CI 0.804-1.000),FDG PET为0.889(95%CI 0.689-0.999)。
临床应用与阅片要点
- 作者认为FAPI PET可能是在评估胰腺癌原发灶、淋巴结转移和远处转移方面优于[18F]FDG的替代方法。
- 多种放射性标记的FAPI变体在胰腺癌诊断中显示出有前景的结果。
- FAPI PET显像有助于临床医生诊断和分期胰腺癌。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Recent studies have shown the potential of fibroblast activating protein inhibitor (FAPI) PET imaging for pancreatic cancer assessment.
PURPOSE: This article is dedicated to comparing the diagnostic efficacy of FAPI PET and [18F]fluorodeoxyglucose (FDG) PET in the evaluation of primary tumors, lymph nodes, and distant metastases in pancreatic cancer.
METHODS: In this review, we conducted a systematic search of studies published in PubMed and Web of Science databases up to September 18, 2023. All included studies used radionuclide labeled FAPI and FDG as PET diagnostic tracers to evaluate their applicability in patients with pancreatic cancer.
RESULTS: The FAPI PET imaging group showed significantly higher sensitivity in the detection of primary lesions (1.000, [95% CI: 0.999-1.000]), lymph node metastases (0.624 [95% CI: 0.391-0.834]) and distant metastatic (0.965 [95% CI: 0.804-1.000]) in pancreatic cancer compared to the FDG PET imaging group (0.889 [95% CI: 0.788-0.966], 0.373 [95% CI: 0.163-0.606] and 0.889 [95% CI: 0.689-0.999], respectively). Furthermore, the maximum standardized uptake value (SUVmax) in FAPI PET imaging is significantly higher than that in FDG imaging for primary lesions (mean difference (MD) = 7.51, 95% CI: 5.34-9.67).
CONCLUSION: Compared with [18F]FDG PET/CT, FAPI PET imaging showed higher sensitivity, SUVmax. This method can be effectively utilized for the evaluation of pancreatic cancer.
CLINICAL RELEVANCE STATEMENT: Fibroblast activating protein inhibitor PET may be a better alternative to [18F]FDG in evaluating primary pancreatic cancer, lymph node metastases, and distant metastases.
KEY POINTS: Fibroblast activating protein inhibitor (FAPI) PET is compared with FDG PET for evaluating pancreatic cancer. Multiple radiolabeled FAPI variants have shown promising results in the diagnosis of pancreatic cancer. FAPI PET imaging effectively helps clinicians diagnose and stage pancreatic cancer.
引用
- Tang R, Liu M, Shu Q, et al. Performance of fibroblast activating protein inhibitor PET imaging for pancreatic neoplasms assessment: a systematic review and meta-analysis. Eur Radiol. 2024. PMID: 38907099. doi:10.1007/s00330-024-10843-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。